Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower
risk of the safety events of interests in patients with peripheral arterial disease
(PAD)
Secondary objectives:
- To compare the risk of bleeding adverse events, serious adverse events and overall
safety of clopidogrel with ticlopidine
- To compare the risk of vascular events of clopidogrel with ticlopidine
- To document the long-term safety of clopidogrel for a total of 52 weeks
- To document the vascular events of clopidogrel for a total of 52 weeks